Rescue your lead compound with the benefit of combination
Combination therapies are emerging as superior treatment options for many diseases, including oncology. Utilizing drug combinations, clinicians can boost efficacy of lead compounds or overcome drug resistance mechanisms.
Why not reach out to start your project now?
We have spent more than a decade designing and refining our automated platform and proprietary Chalice software. With our platform, you can profile your compounds as single agents or combinations across hundreds of well-annotated cancer cell lines, and gain actionable insights in a short period of time.
Our HT combination screening platform operates by using sophisticated bioinformatics tools, which can assess drug or compound combinations over a defined range to look for synergistic or antagonistic effects. These may be observed either as an increase in the anti-proliferative or cell killing effect, or as potency shift such that lower dosages are required to see the same therapeutic effect.
Combination effects can manifest as efficacy boosts (orange line) or potency shifts (blue line)
Once the effect of each compound as a single agent is removed, an Excess Matrix is generated that provides a simple visual representation of information about combination activity at the multiple concentrations and ratios of the two drugs and where synergies or antagonism can be seen.
ATL313, A Potent, and Selective A2A Agonist as a Novel Drug Candidate for the Treatment of Multiple Myeloma
Identification of Combinatorial Drugs that Synergistically Kill Both Eribulin-Sensitive and Eribulin-Insensitive Tumor Cells
Pharmacogenomic Investigation of Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765): Drug Sensitivity in Diffuse Large B-Cell Lymphoma (DLBCL) Within a Tumor Microenvironment–Aligned High-Throughput Screen